Biovaxys Technology Corp (TSE:BIOV) has released an update.
BioVaxys Technology Corp., a clinical-stage biopharmaceutical company, is on track to file its delayed annual and interim financial statements by May 13, 2024, after a recent acquisition required more time for auditing. The company reassures stakeholders that no further material changes have occurred since the initial default announcement and that they are not undergoing any insolvency proceedings. BioVaxys continues to adhere to alternative information guidelines and commits to bi-weekly status updates amidst the filing delay.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
